Antimicrobial biomaterials from bio-based feedstocks with novel feedstock supplementation strategies

采用新型原料补充策略的生物基原料制成的抗菌生物材料

• 批准号: 10063453
• 金额: $ 6.97万
• 依托单位: EVOLUTOR LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10063453
• 关键词: Antimicrobial; biomaterials; bio; based; feedstocks

Both the climate crisis and public health crises such as the COVID-19 pandemic are presenting substantial challenges to our communities and economies.To address the climate collapse, we need to rapidly reduce our manufacturing industries' reliance on fossil fuels and build new decarbonised supply chains that are robust and resilient in an ever-changing world.In 2016/2017 healthcare associated infections cost the NHS £2.1B, and were responsible for approximately 22,800 inpatient deaths. To protect public health and reduce the burden on health care providers, we need new technologies and products that can reduce the spread of microbial pathogens carrying healthcare associated infections such as scarlet fever, strep A and bacterial co-infections that accompany conditions like COVID-19\. As well as fulfilling these functions, new products must also be manufacturable without any reliance on fossil fuels.In this project, Evolutor is addressing these challenges by developing production processes for the manufacture of advanced and highly-functionalized biomaterials with antimicrobial properties. We will use our specialist Accelerated Evolution Platform to develop microbial production hosts that, through precision fermentation, can turn waste products into biomaterials that are fully biodegradable and biocompatible. Additionally, we will test new strategies and manufacturing processes to impart natural antimicrobial properties to these materials by supplementing fermentation feedstocks with a range of natural compounds.Through these project outputs, we will produce and analyse the performance of several small batches of novel biomaterial that:* is 100% natural;* has customizable antimicrobial functionality;* is produced from waste;* requires no direct fossil fuel input;* is completely biodegradable and non-toxic;* produces significantly less chemical pollution than conventional materials; and* can be tailored to a wide range of applications.Overall, the success of this project will drive the expansion of the UK's bioeconomy, bring us closer to a Net Zero world, and help to reduce the spread of microbial pathogens and the burden of associated healthcare costs. It will also accelerate Evolutor's ambition to build its world-leading bio-foundry Galapagos Towers in the North of England.Beyond the completion of this project, the innovations achieved will allow Evolutor to explore scaled-up manufacture of its antimicrobial biomaterials as well as conduct onward R&D of feedstock supplementation to customise material properties beyond antimicrobial functionality. Example properties include colour (for advanced clothing and construction materials), fragrance (for cosmetics and detergents), tensile strength (for industrial and construction use) and permeability (for wastewater treatment and pollution control).

气候危机和公共卫生危机（例如 COVID-19 大流行）都给我们的社区和经济带来了巨大挑战。为了应对气候崩溃，我们需要迅速减少制造业对化石燃料的依赖，并建立新的脱碳供应链2016/2017 年，医疗保健相关感染给 NHS 造成了 2.1B 英镑的损失，并造成约 22,800 例住院患者死亡，以保护公众健康并减轻医疗保健负担。对于供应商来说，我们需要新技术和产品来减少携带相关医疗保健感染（例如猩红热、A 型链球菌和伴随着 COVID-19 等疾病的细菌混合感染）的微生物病原体的传播，同时还需要新产品来实现这些功能。还必须能够在不依赖化石燃料的情况下进行制造。在这个项目中，Evolutor 正在通过开发生产具有抗菌特性的先进和高功能化生物材料的生产工艺来应对这些挑战，我们将使用我们的专业加速材料。进化平台开发微生物生产宿主，通过精密发酵，可以将废物转化为完全可生物降解和生物相容的生物材料。此外，我们将测试新的策略和制造工艺，通过添加发酵原料来赋予这些材料天然抗菌特性。通过这些项目成果，我们将生产并分析几小批量新型生物材料的性能，这些材料：* 100% 天然；* 具有可定制的抗菌能力功能性；* 功能性是从废物中产生的；* 不需要直接输入化石燃料；* 完全可生物降解且无毒；* 产生的化学污染比传统材料少得多；并且* 可针对广泛的应用进行定制。该项目的成功将推动英国生物经济的扩张，让我们更接近净零世界，并有助于减少微生物病原体的传播和相关医疗费用的负担，还将加速 Evolutor 实现其建设雄心的目标。世界领先位于英格兰北部的加拉帕戈斯塔生物铸造厂。该项目完成后，所取得的创新将使 Evolutor 能够探索其抗菌生物材料的规模化生产，并进一步进行原料补充剂的研发，以定制除抗菌功能之外的材料特性示例属性包括颜色（用于高级服装和建筑材料）、香味（用于化妆品和洗涤剂）、拉伸强度（用于工业和建筑用途）和渗透性（用于废水处理和污染控制）。